Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

A Trial for Patients With Advanced/Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Intraepithelial Neoplasia
Uterine Neoplasms
Genital Neoplasms, Female

Interventions: Drug: Pemetrexed

First Posted Date: 2005-09-19

Last Posted Date: 2009-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT00190983

Locations: 🇺🇸
Gynecologic Oncology Group 215-854-0770, Philadelphia, Pennsylvania, United States

A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: pemetrexed
Drug: cyclophosphamide

First Posted Date: 2005-09-19

Last Posted Date: 2009-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 103

Registration Number: NCT00190671

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Saint Petersburg, Russian Federation

A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver

Phase 2

Completed

Conditions: Liver Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2007-11-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT00191412

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Denver, Colorado, United States

A Trial for Patients With Gestational Trophoblastic Disease

Phase 2

Completed

Conditions: Trophoblastic Neoplasms
Uterine Neoplasms
Hydatidiform Mole
Choriocarcinoma

First Posted Date: 2005-09-19

Last Posted Date: 2007-08-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 50

Registration Number: NCT00190918

Locations: 🇺🇸
Gynecologic Oncology Group 215-854-0770, Philadelphia, Pennsylvania, United States

Molecular Profiling in Lung Cancer Patients

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Carcinoma

Interventions: Drug: pemetrexed
Drug: cisplatin
Procedure: Radical Non-Small Cell Lung Cancer (NSCLC) surgery

First Posted Date: 2005-09-19

Last Posted Date: 2011-10-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT00191308

Locations: 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2005-09-16

Last Posted Date: 2005-11-07

Lead Sponsor: Celgene Corporation

Target Recruit Count: 40

Registration Number: NCT00179699

Locations: 🇺🇸
MD Anderson - Orlando, Orlando, Florida, United States
🇺🇸
Washington University, St. Louis, Missouri, United States
🇺🇸
North Shore Hem/Onc Associates, East Setauket, New York, United States

and more 2 locations

Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: pemetrexed
Drug: cyclophosphamide
Drug: doxorubicin
Drug: docetaxel

First Posted Date: 2005-09-08

Last Posted Date: 2012-03-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 257

Registration Number: NCT00149214

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer
Non Small Cell Lung Carcinoma

Interventions: Drug: Pemetrexed
Drug: Matuzumab

First Posted Date: 2005-05-27

Last Posted Date: 2018-04-06

Lead Sponsor: EMD Serono

Target Recruit Count: 150

Registration Number: NCT00111839

Locations: 🇺🇸
University of Southern California/Norris Cancer Center, Los Angeles, California, United States
🇺🇸
Peachtree Hematology and Oncology, Atlanta, Georgia, United States
🇺🇸
Georgia Cancer Specialists, Tucker, Georgia, United States

and more 40 locations

Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy

Phase 2

Completed

Conditions: Ovarian Neoplasms
Primary Peritoneal Cancer

First Posted Date: 2005-04-25

Last Posted Date: 2007-05-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 100

Registration Number: NCT00109096

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sutton, United Kingdom

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Breast Neoplasms, Male
Carcinoma, Ductal

Interventions: Drug: pemetrexed

First Posted Date: 2005-03-21

Last Posted Date: 2009-06-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 37

Registration Number: NCT00106002

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy